Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. India
  4. NSE India Stock Exchange
  5. Aurobindo Pharma
  6. News
  7. Summary
    AUROPHARMA   INE406A01037

AUROBINDO PHARMA

(AUROPHARMA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Companies make progress tackling drug-resistant infections, foundation says

11/17/2021 | 07:16pm EST
FILE PHOTO: Ten pills of the antibiotic

(Reuters) - Drugmakers have made some progress in restraining antibiotics overuse, which leads to drug-resistant infections, but have fallen short in making antibiotics more widely available in low-income countries, an influential foundation said.

For the third time since 2018 and 2020, the non-profit Access to Medicine Foundation (AMF) has analysed how companies are dealing with the two-pronged challenge of making bacteria-fighting drugs more widely available in poor countries while also reining in the type of excess use that is known to foster superbugs.

Unwarranted use of antibiotics - not only a first-world problem but also widespread in loosely regulated markets including Thailand, India and parts of Africa - increases the risk of treatable pathogens developing escape mechanisms against established drugs.

In the United States alone, more than 35,000 people die each year from antibiotic-resistant infections, according to a report by the U.S. Centers for Disease Control and Prevention. A European Union public health body has put the number of annual deaths in the region at about 33,000.

In its Antimicrobial Resistance Benchmark report published on Thursday, AMF said companies including GlaxoSmithKline, Pfizer and Aurobindo have made some strides in areas such as preventing antibacterial waste spilling into the environment or shunning volume-based promotion tactics.

Thanks mainly to its development of new antibiotics and responsible manufacturing, GSK scored best among large pharmaceutical companies against a range of targets in AMF's ranking for responsible access to antimicrobial drugs.

Pfizer was a close second mainly on the strength of its stewardship to avoid overuse or misuse, antibiotic waste management and access to drugs in poor countries.

Aurobindo led a ranking of generic drugmakers thanks to activities including avoiding overuse.

Overall, however, manufacturers were still not doing enough to bring their products to poorer parts of the world, the report added.

"Companies are not taking the necessary steps to provide access to the antibiotics and antifungals in their portfolios in low- and middle-income countries - and where access strategies are in place, they remain focused on a small set of countries, people, and diseases," AMF said.

AMG, based in Amsterdam, is funded by Britain, the Netherlands, the Gates Foundation, AXA Investment Managers and the Wellcome Trust.

(Reporting by Ludwig Burger; Editing by Steve Orlofsky)

By Ludwig Burger


ę Reuters 2021
Stocks mentioned in the article
ChangeLast1st jan.
AUROBINDO PHARMA 0.25% 670.5 Delayed Quote.-8.93%
GLAXOSMITHKLINE PLC -1.68% 1672.6 Delayed Quote.5.89%
All news about AUROBINDO PHARMA
01/14Aurobindo Pharma Gets US FDA Warning Letter for Hyderabad, India Unit; Shares Plunge 4%
MT
01/11Aurobindo Pharma Unit Expands Biosimilars Distribution Deal with Orion to Include Europ..
MT
01/11Orion, CuraTeQ Biologics Broaden Biosimilar Distribution Deal To Include Baltic Countri..
MT
01/11Aurobindo Pharma in Talks to Sell Stake in Injectibles Business for As Much As $700 Mil..
MT
01/11Several Firms Reportedly Sounded Off to Buy Stake in Injectable Business of Aurobindo P..
CI
01/06Aurobindo Pharma Launches COVID-19 Treatment Drug Molnaflu
MT
01/02Aurobindo Pharma Appoints New Managing Director
MT
01/01Aurobindo Pharma Limited Announces Board Changes
CI
01/01Aurobindo Pharma Limited Announces Executive Changes
CI
2021Aurobindo Pharma Gets Approval to Sell Generic Version of Molnupiravir in India
MT
More news
Analyst Recommendations on AUROBINDO PHARMA
More recommendations
Financials
Sales 2022 243 B 3 271 M 3 271 M
Net income 2022 30 757 M 413 M 413 M
Net cash 2022 16 235 M 218 M 218 M
P/E ratio 2022 12,7x
Yield 2022 0,61%
Capitalization 393 B 5 283 M 5 278 M
EV / Sales 2022 1,55x
EV / Sales 2023 1,38x
Nbr of Employees 19 364
Free-Float -
Chart AUROBINDO PHARMA
Duration : Period :
Aurobindo Pharma Technical Analysis Chart | AUROPHARMA | INE406A01037 | MarketScreener
Technical analysis trends AUROBINDO PHARMA
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 28
Last Close Price 670,50 INR
Average target price 871,64 INR
Spread / Average Target 30,0%
EPS Revisions
Managers and Directors
Kambam Nithyananda Reddy Vice Chairman & Managing Director
Santhanam Subramanian Chief Financial Officer
Kannan Ragunathan Non-Executive Chairman
B. Adi Reddy Secretary & Compliance Officer
Avnit Bimal Singh Independent Non-Executive Director
Sector and Competitors
1st jan.Capi. (M$)
AUROBINDO PHARMA-8.93%5 255
JOHNSON & JOHNSON-2.32%439 907
ROCHE HOLDING AG-3.75%322 066
PFIZER, INC.-8.37%303 712
ABBVIE INC.1.02%241 811
ELI LILLY AND COMPANY-10.55%223 992